BRILIQUE® (ticagrelor)

BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with aspirin to protect patients with prior MI and a high risk* of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings†6

*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)

BRILIQUE (ticagrelor) 90mg b.d. in combination with  ASA is indicated for patients with Acute Coronary Syndromes (ACS) for up to 12 months. BRILIQUE (ticagrelor) 90mg b.d. is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment

Mode of Action

BRILIQUE is not a thienopyridine24

BRILIQUE is in a chemical class called cyclopentyltriazolopyrimidines (CPTPs). It is the first reversibly binding oral adenosine diphosphate (ADP) receptor antagonist.6

BRILIQUE is different from a thienopyridine, because of the following: 

BRILIQUE is direct acting, provides 24-hour systemic exposure, is a reversible binder to the P2Y12 receptor and acts via both P2Y12 and ENT-1
BRILIQUE is direct acting, provides 24-hour systemic exposure, is a reversible binder to the P2Y12 receptor and acts via both P2Y12 and ENT-1

*A link between increases in adenosine and clinical outcomes has not been clearly elucidated